Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Autor: M B Manning, D A Streja, C Keller, C H Chung, P L Beckett, A Özdemir, Y M Cho, I Colin, L J Aronne, Erik Christiansen, Markus Laimer, L Van Gaal, S N Lederman, T M O'Connor, L J Klaff, S Aronoff, S H Baik, A V Murray, Signe O R Wallenstein, N A Godbole, H O Høivik, Dilek Gogas Yavuz, A Golay, G T'Sjoen, B Delgado, I N El Ebrashy, E S Kang, C Wium, Bruce W. Bode, Ramazan Sari, B A Palchick, J Geohas, P R Nicol, M Winnie, N Aladağ, E W Braun, C Vercammen, S A Shelbaya, K Sivalingam, S Gorban de Lapertosa, E Riffer, F G Eliaschewitz, J B Buse, B Schultes, C H Sorli, K-W Lee, Mark Warren, T Pieber, S Stäuble, R Prager, A Mertens, A A Arif, D C Eagerton, A Scheen, I J Kim, J A Seo, S Ong, E Ataoglu, John B. Buse, D Berker, A White, F Helland, J C LaRocque, Young Min Cho, Christin L. Hertz, E M Palace, L H S Canani, M P Finneran, S H A Khalil, H L Gulseth, D Weiss, J Condit, E Fließer-Görzer, L Rista, S Akın, M H M F El Hefnawy, N H Kim, C Issa, S Bilz, H Bays, S Fischli, V Preumont, J Pereles-Ortiz, B Bode, E J Morawski, Aytekin Oguz, J Cooper, Tamer Tetiker, Ann Mertens, G Rudofsky, Thomas R. Pieber, W R Litchfield, J L Gross, D L Weinstein

Publikováno v: The lancet. Diabetesendocrinology. 7(7)

BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e132376f3cbf48c52376523aef27e59f
https://pubmed.ncbi.nlm.nih.gov/31320282

Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes

Autor: V, Preumont, M P, Hermans, M, Bergman, M, Buysschaert

Publikováno v: Acta clinica Belgica. 67(6)

We prospectively analysed HbA1c changes after 12 months of exenatide therapy and determined which baseline clinical and/or biological factors predict response.Open-label cohort of 41 subjects with type 2 diabetes (56% male) poorly-controlled on maxim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bd106f23256be7d08d1a0f2fecbac8d5
https://pubmed.ncbi.nlm.nih.gov/23340146

One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice

Autor: M, Buysschaert, V, Preumont, P R, Oriot, I, Paris, M, Ponchon, D, Scarnière, P, Selvais, C, Warnotte

Publikováno v: Diabetesmetabolism. 36(5)

AIM: The study objective was to analyze, in everyday practice, the long-term metabolic effects of exenatide (for 9 and 12months) in patients with type 2 diabetes not responding to treatments with metformin and sulphonylurea at maximum dosages. METHOD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeeb07dc3f1b0aa1e1222d23f2a577fd
https://pubmed.ncbi.nlm.nih.gov/20598606